Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Immune Regulation + Chemotherapy in MRD-positive Colorectal Cancer
NCT06434376Phase 1Enrolling by invitation
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in colorectal cancer (CRC), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Primary endpoint: Objective Response Rate. Started Jul 2024; status: enrolling by invitation.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06434376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434376.